Mineralys Therapeutics, Inc. (MLYS)
NASDAQ: MLYS · Real-Time Price · USD
38.50
-0.41 (-1.05%)
Dec 5, 2025, 4:00 PM EST - Market closed
Mineralys Therapeutics Employees
Mineralys Therapeutics had 51 employees as of December 31, 2024. The number of employees increased by 23 or 82.14% compared to the previous year.
Employees
51
Change (1Y)
23
Growth (1Y)
82.14%
Revenue / Employee
n/a
Profits / Employee
-$3,360,059
Market Cap
3.05B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 51 | 23 | 82.14% |
| Dec 31, 2023 | 28 | 16 | 133.33% |
| Dec 31, 2022 | 12 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
MLYS News
- 8 days ago - This Fund Leaned Into 2025's Big Biotech Rally with a $9.5 Million Bet on Mineralys - The Motley Fool
- 9 days ago - Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 25 days ago - Mineralys Therapeutics, Inc. (MLYS) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 25 days ago - Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 weeks ago - Data for Lorundrostat in Chronic Kidney Disease and Hypertension Presented at American Society of Nephrology (ASN) Kidney Week 2025 - GlobeNewsWire
- 6 weeks ago - Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 2 Explore-CKD Trial of Lorundrostat at American Society of Nephrology (ASN) Kidney Week 2025 - GlobeNewsWire
- 2 months ago - Mineralys: Lorundrostat Continues To Deliver Hypertension Market Expansions - Seeking Alpha
- 2 months ago - Mineralys Therapeutics Completes Enrollment in Phase 2 EXPLORE-OSA Trial of Lorundrostat in Obstructive Sleep Apnea and Hypertension - GlobeNewsWire